NetworkNewsWire Editorial Coverage: The legal marijuana market
continues to gain momentum, driven by increasing public acceptance
and an increasing number of investors looking for viable
opportunities on a crowded playing field. According to a recent
Gallup poll1, 60 percent of Americans now support the
legalization of marijuana. As the playing field continues to grow
in diversification and size, some of the most recognizable and
frequently seen names are ChineseInvestors.com, Inc. (CIIX)
(CIIX
Profile), Terra Tech Corp.
(TRTC), Medical Marijuana, Inc. (MJNA),
Marijuana Company of America, Inc. (MCOA) and
CV Sciences, Inc. (CVSI).
The market presence of ChineseInvestors.com, Inc.
(CIIX) is increasing significantly as the company
continues to diversify its entry points into the cannabis space.
CIIX aims to become the world’s leading publicly traded Chinese
medical cannabis company and is focused on investing in the
distribution and R&D of cannabidiol-based (CBD) health products
and medicines to Chinese-speaking customers throughout the
world.
Though marijuana is currently illegal in China, cannabis-based
oils are not, which gives CIIX prime access to a market of almost 2
billion customers in China. Additionally, CIIX is expanding its
footprint to other countries, having recently incorporated CBD
Biotechnology Inc. in British Columbia, Canada. This subsidiary
will focus on R&D and distribution of health products that
include hemp-based CBD, food and beverage items in Canada.
Recently, CIIX released (http://nnw.fm/w3pbB) news that its wholly owned
Chinesehempoil.com, Inc. subsidiary will now officially accept
bitcoin payments, enabling customers purchasing hemp-based health
products, foods and beverages to use bitcoin alongside other more
common payment methods like PayPal and credit cards. This will
enable cannabis customers to complete non-cash transactions in
countries with government restrictions in place that limit banking
options for cannabis businesses, like the United States.
CIIX is additionally readying its first retail store to open for
business in the primarily Chinese community of San Gabriel,
California. This store will be among the first to offer CIIX’s new
OptHemp health product line, which includes the company’s first
private label product, OptHemp Ultra Premium Hemp Oil. OptHemp has
been launched by Chinesehempoil.com and is crafted using a formula
that has been optimized for management of inflammation and pain. It
is GMO-free and is grown in organic farms in Colorado using a CO2
extraction technology.
The December 2016 launch of the ChineseCBDoil.com website in the
free-trade zone of Shanghai, China, was another CIIX milestone.
This site is the first CBD health products online store to be
offered in the Chinese language, and, alongside its launch, the
company additionally introduced the first Chinese language
Yelp-style social media app, which offers a database of cannabis
dispensaries and marijuana strains along with a platform for
reviewing and discussing cannabis products, maps of dispensary
locations and more. The app has been approved by the Apple
store.
A May 2017 research report issued by Consilium Global Research
(http://nnw.fm/a13sJ) projected that CIIX will
grow at a CAGR of about 100 percent through 2020 and that the
company will attain revenues of $14.8 million by fiscal year 2020,
while the underlying market is expected to grow at a rate of 80
percent.
Another promising legal cannabis play is Terra Tech
Corp. (TRTC), a vertically integrated agriculture company
with multiple subsidiaries in the medical cannabis space. The
company’s focus is on consistently cultivating and providing
high-quality medical marijuana to qualified, registered medical
marijuana establishments while furthering researching in the
medical cannabis industry to eventuate the cultivation and
cross-breeding of marijuana strains that can treat various
ailments. Terra Tech is uniquely positioned to operate safe and
successful medical marijuana cultivation facilities throughout the
United States as cannabis use approval advances across the country.
The company recently received its Dual Use Marijuana business
licenses from the state of Nevada, enabling its four Blüm cannabis
dispensaries in that state to begin adult-use cannabis sales.
Medical Marijuana, Inc. (MJNA) is distinguished
as the first company to have made hemp-based CBD products available
in the U.S. and globally, having found legal means of offering
these products in the U.S. despite federal restrictions on
cannabis. MJNA is providing high-quality cannabis-derived products
that feature non-psychoactive cannabinoids like CBD, which boasts
various potential health applications independent of reliance on
tetrahydrocannabinol (THC). Going outside the U.S. to grow low-THC
varieties of cannabis (hemp), MJNA offers CBD hemp oil from
carefully cultivated hemp plants and imports it into the U.S. CBD
hemp oil is fully legal in the U.S. and is non-psychoactive,
containing a full spectrum of phytocannabinoids and high CBD
content with almost no THC. MJNA’s products include pure CBD oil,
oil capsules, oil chewing gum, oil tinctures, sprays and liquids,
as well as CBD vaporizers, vape oil, vaporizer pens, and hemp oil
body care. In addition to MJNA’s success in offering legal
hemp-based CBD products in the U.S., the company has also broken
into markets in Mexico, Brazil and Europe. The first office for
MJNA’s subsidiary, HempMeds Mexico, opened in Monterrey, Nuevo
Leon, Mexico in June 2017.
Marijuana Company of America (MCOA) markets and
distributes hemp to provide investors an opportunity to be at the
forefront of cannabis and hemp innovation, cultivation, processing
and distribution. MCOA’s focus is on producing a diverse portfolio
of synergistic companies that deliver value to shareholders. The
company’s vertically integrated business model has ideally
positioned it and its partners for rapid growth. MCOA’s portfolio
of brands, investments and joint ventures includes hempSMART, Club
Harmoneous, Bougainville, GateC Research, and MoneyTrac
Technology.
Another interesting marijuana play, CV Sciences, Inc.
(CVSI), operates two distinct business segments: a drug
development division focused on the development and
commercialization of novel therapeutics using synthetic CBD; and a
consumer product division that manufactures, markets and sells
plant-based CBD products. The company’s pharmaceutical division is
focused on developing synthetically formulated CBD-based medicines
and is pursuing FDA approval for drugs that have specific
indications utilizing CBD as the active pharmaceutical ingredient.
The company has achieved promising preclinical results in
developing CBD medicines for the treatment of a variety of medical
conditions, with its pipeline currently including CVSI-007 to
support the cessation of smokeless tobacco use and addiction. The
company’s consumer products include PlusCBD Oil and Purified
Liquids.
For investors seeking action in the legal marijuana market, the
named companies offer the chance to participate in an interesting
array of industry niches, making the case for further due diligence
and market research.
Editorial Sources:
(1) Gallup http://nnw.fm/Cq0ZA
(2) Arcview http://nnw.fm/HWqF6
For more information on ChineseInvestors.com please visit:
ChineseInvestors.com (CIIX) or www.ChineseInvestors.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to
users (1) access to our news aggregation and syndication servers,
(2) enhanced press release services, and (3) a full array of social
communication solutions. As a multifaceted financial news and
content distribution company with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. NNW
has an ever-growing distribution network of more than 5,000 key
syndication outlets across the country. By cutting through the
overload of information in today's market, NNW brings its clients
unparalleled visibility, recognition and brand awareness. NNW is
where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer's filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer's securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com